Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)


 1.03 (0.00%)

Market Cap$4,442,467,684

02/05/16  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda 02/04/16

Read more

Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2015 Financial Results on February 9, 2016 01/20/16

Read more


4th Quarter & Year 2015 Financial Results Conference Call02/09/16 4:30 p.m. ETView event34th Annual J.P. Morgan Healthcare Conference01/11/16 2:30 p.m. PTView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources